The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are one of several classes of agents now available to treat metastatic, or advanced, breast cancer. Although advanced breast cancer is rarely curable, these agents are among those that now make it more treatable, leading to improved 5-year survival rates among women with some forms of advanced disease. This interactive review discusses where these agents fit into current clinical pathways and describes how to best match particular CDK4/6 inhibitors to individual patients. The role of NPs and PAs in care is emphasized, including how to manage potential side effects and improve patient adherence to therapy. With carefully planned disease management, treatment for advanced breast cancer can delay disease progression, prolong life, minimize the toxicities of therapy, and maintain quality of life.
eNewsletter with interactive benchmarking
After completing this activity, participants should be better able to:
- Apply current evidence and guideline recommendations to identify the appropriate use of CDK4/6 inhibitors in clinical practice for patients with HR+/HER2– advanced breast cancer
- Describe recommended pretreatment evaluations and monitoring for patients taking CDK4/6 inhibitors
- Incorporate dosing requirements and side-effect management strategies for patients taking CDK4/6 inhibitors
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Course director: Lee Schwartzberg, MD, FACP, West Cancer Center, Germantown, Tennessee
CNE course advisor: Heather Greene, MSN, FNP, AOCNP, West Cancer Center, Germantown, Tennessee
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until August 15, 2020. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Richard Lindsay, PA-C, MD Anderson Cancer Center, Houston, Texas
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from Agios; Astellas Pharma Inc.; Astellas and Pfizer, Inc.; Bristol-Myers Squibb; Celgene Corporation; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; and Sanofi Genzyme.
This activity is supported by an educational grant from from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Schwartzberg: consultant: Amgen, AstraZeneca, Pfizer.
None of the members of the Planning Committee, CE Alliance staff, or independent reviewer have any relevant relationships to disclose, except Dr Schwartzberg as noted above.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 15, 2019
Expiration date: August 15, 2020
© 2020 Practicing Clinicians Exchange. All Rights Reserved. OPCE94719-7C